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12 plant species traditionally used by the Mapuche people in Chile to treat wounds and inflammations have been evaluated
for their direct blood platelet inhibition. Seven of the 12 tested plant species showed platelet inhibitory eﬀect in sheep blood,
and four of these were also able to inhibit the ADP- (5.0 μM) and collagen- (2.0 μg/mL) induced aggregations in human blood.
These four species in respective extracts (in brackets) were Blechnum chilense (MeOH), Luma apiculata (H2O), Amomyrtus luma
(DCM :MeOH 1 : 1) andCestrum parqui (DCM :MeOH 1 : 1). The platelet aggregating inhibitory eﬀects ofA. luma (DCM :MeOH
1 : 1), and L. apiculata (H2O) were substantial and confirmed by inhibition of platelet surface activation markers.
1. Introduction
Chile has an extraordinary variety of plants and animals,
thanks to the latitudinal extent of the country and its great al-
titudinal range. The ChileanWinter Rainfall-Valdivian forest
is one of the most exceptional and exposed biodiversity hot-
spots of the world. It encompasses approximately 40% of
Chile’s land area and harbours both endemic flora and fauna.
About 50% of the 4000 vascular plant taxa found in this area
are endemic. Through collaboration, we have access to the
traditional medicinal plants from this area [1–3]. The plants
examined are traditionally used by the Mapuche people in
Chile to treat wounds and associated infections, as shown in
Table 1. This paper evaluates the platelet inhibitory capacity
of 12 selected plant species.
Platelet receptors on the surface of the platelets determine
the reactivity of platelets and have a wide range of agonists
and adhesive proteins [7]. Current antiplatelet therapies tar-
get key pathways of platelet activation, including surface
receptors and signalling molecules. Aspirin has been the
foundation of antiplatelet therapy for over 50 years, and it
inhibits platelets by irreversibly acetylating Ser529 of
cyclooxygenase 1 (COX1), thereby inhibiting thromboxane
A2 formation by the platelets. Aspirin has been shown to
reduce vascular death in high-risk patients by 15% and non-
fatal vascular events by 30%, as evidenced bymeta-analysis of
over 100 randomized trials [8–10]. Several medicinal plants
have direct or indirect antiplatelet eﬀects, many through
inhibition of COX1 or 2. Likewise, a variety of fruit extracts
have been tested in vitro for their antiplatelet property, and
tomatoes have been found to have a very high activity [11].
It was showed that tomato extract inhibited both ADP- and
collagen induced aggregation by up to 70% but not AA-
induced platelet aggregation. Various fruit juices have also
been tested, and some flavonoids have been established as
inhibitors of collagen-induced platelet activity [12, 13]. The
eﬀect of flavonoids is well established, and for coﬀee, it was
showed that the caﬀeine is not the inhibitor [14] but rather
the phenolics that was also found inside the platelets. Many
of the eﬀects observed are often due to synergistic eﬀects,
which is also seen on tomato and grape juice, and the eﬀect
can be expected to be lower for the individual compounds
[11–14].
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Table 1: Overview of the plants examined for blood aggregation inhibition, including voucher number, Latin name, local name, and use.
All the plants have been collected in region X in the Valdivian Coastal Range Forest. L: leaf, S: stem, R: root, W: whole plant, T: thorn, and F:
flower.
Family
Voucher
number
Latin plant name
Collected
part
Common
name
Local use
Araliaceae PM01-44
Pseudopanax laetevirens (Gay.)
Baill.
L, S Sauco
Leaves, fruit and bark are used for wound
healing, as anti-inflammatory, laxative
and as diuretic [3]
Asteraceae PM01-28
Baccharis absinthioides Hook. &
Arn.
L
Baccharis leaves are used for wound
healing, as anti pyretic and analgesic [4]
Blechnaceae PM01-18 Blechnum chilense (Kaulf.) Mett. L, S, R
Costilla de
vaca
The whole plant is used towards
gonorrhoea and wound and eye
infections [3]
Gunneraceae PM01-09 Gunnera chilensis Lam. L, S Nalca
Stem and root are used against uterus
pains, as haemostatic and
anti-inflammatorial [3]
Lamiaceae PM06-38
Satureja multiflora Briq. in Engl
& Prantl
L Oreganillo Leaves used for digestive problems [5]
Malvaceae PM01-10
Corynabutilon vitifolium (Cav.)
Kearney
L, S Huella
Bark, stem and leaves are used for liver
diseases and uterus contractions [3]
Myrtaceae PM03-24
Amomyrtus luma (Molina) D.
Legrand & Kausel
L, S Luma
Leaves are used to decrease blood
pressure and cholesterol levels, and to
treat liver diseases [3]
Myrtaceae PM01-40 Luma apiculata (DC.) Burret L, S
Arraya´n,
Quetri
Leaves are used to treat diarrhea,
dysentery, ingestion [6]
Myrtaceae PM01-16 Ugni molinae L, S Murta The fruit is stimulating and refreshing [3]
Onagraceae PM+1-19 Fuchsia magellanica Lam. L, S
Leaves are used as antipyretic, blood
pressure regulator, diuretic and wound
healing [3]
Poaceae PM03-32
Anthoxanthum utriculatum (Ruiz
& Pav.) Y. Schouten & Veldkamp
L Ratonera Roots are used traditionally [3]
Proteaceae PM03-25 Lomatia ferruginea (Cav.) R.Br. L, R
Lomatia leaves and bark are used as
laxative, expectorant and as
anti-inflammatory [3]
Solanaceae PM05-35 Cestrum parqui L’He´r L Palqui
Leaves are used to relief fevers, and
towards skin diseases [3]
Winteraceae PM07-05 Drimys winteri J.R. & G. Forster L, B
Leaves are used as antipyretic, in wound
healing, as diurectic anti inflammatory
agent, and against ulcers [3]
The plants collected for this study have been chosen
based on their use in the treatment of wounds and inflam-
matory diseases [1, 2]. Many inflammatory mechanisms are
involved in wound healing. Especially, platelets plays a crucial
role in haemostasis and thrombosis, and they also play an
important role in wound healing, inflammation, antimi-
crobial host defence, angiogenesis, and tumour growth and
metastasis [15]. Therefore, plants used against these or re-
lated diseases have been collected. The plants examined
in here are collected based on ethnopharmacological data
from the Region de Los Lagos in southern Chile, part of
the Chilean Winter Rainfall-Valdivian forest [3, 16, 17].
Deforestation threatens this area, and the evaluation of
traditional medicine might help to preserve the area with
its natural richness. Furthermore, the evaluation also con-
tributes to the preservation of the Mapuche culture, and a
sustainable production and/or collection of plants may create
an economic foundation as an alternative to the felling of the
rainforest.
The aim of the study was a screening of a variety of
Mapuche herbalmedicine for platelet inhibitory eﬀects. Inhi-
bition on platelet aggregation in sheep blood was chosen as
an initial screeningmethod due to the large volumes of blood
needed. Plant extracts with activity in sheep blood were
subsequently investigated for inhibitory eﬀects on human
blood platelets.
2. Material and Methods
2.1. Plant Material. The plant species in this study are tra-
ditionally used to treat wounds, wound infections, and/or
inflammatory ailments by the Mapuche people. The collec-
tion have been conducted in February in the years 2001,
2003, 2005, 2006, and 2007 under the supervision of Alfonso
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Guzman [18]. All plants have been collected in Region
de Los Lagos located in Chile’s region X. Available plant
parts were collected without destroying the population, for
example, leaves, stems, flowers, and roots though mainly
leaves are used for teas, the preferred preparation inMapuche
traditional medicine (Table 1) [17]. After collection, the
plant material was immediately dried at room temperature
and transported to Denmark for further studies, where it was
kept dry and in darkness until use. Voucher specimens are
stored at the Botanical Garden and Museum, University of
Copenhagen (C); see Table 1 for voucher specimen number.
2.2. Extraction and Sample Preparation. Dried material from
12 diﬀerent species of Chilean plants was subjected to
extraction. 5mL DCM :MeOH 1 : 1 was added to 0.5 g dry
plant material and exposed to ultrasonication for 30 minutes
and filtration. This was repeated twice, and the combined
extracts were evaporated to dryness. This procedure was
repeated using MeOH and finally by H2O. The dried extracts
were stored at −20◦C until used for the aggregation assays.
The screening was conducted in each of these three plant
extracts, DCM :MeOH 1 : 1, MeOH, and H2O. Yield of
extractions are given in Table 2.
2.3. Preparation of Samples for Aggregation and Flow
Cytometry Assays. The dried extracts were dissolved in
DMSO : EtOH 1 : 4 in order to reach a concentration of
20mg/mL, only extracts that was fully redissolved where
taken forward. Tested extracts are listed in Table 2. The
DMSO : EtOH samples were diluted in sterile filtered
HEPES-tyrode’s buﬀer pH 7.4 (137mM NaCl, 2.7mM
KCl, 1.0mM MgCl2, 12mM NaHCO3, 0.4mM Na2HPO4,
5.5mM glucose, 10mM HEPES) for aggregation assays,
and in HEPES-tyrode’s buﬀer with 0.5% BSA for flow
cytometry assays to a final concentration of 1mg/mL. The
DMSO : EtOH samples diluted in HEPES-tyrode’s buﬀer was
added to PRP as a 1 : 10 dilution. HEPES-tyrode’s buﬀer
containing 0.5% DMSO : EtOH 1 : 4 was used as vehicle
control. Sample and vehicle control were incubated in PRP
at 37◦C for 30min before aggregation experiments. Final
concentration of plant extract and vehicle control in the
aggregometer was 0.1mg/mL. A pure MeOH aliquot was
treated as an extract, and the eﬀect of DMSO andMeOHwas
observed in all assays but did not show any significant eﬀect.
2.4. Platelet Aggregation Assay. Platelet aggregation assays
were performed in sheep and human blood in duplicates.
Sheep blood was used for the bulk screenings, where a large
volume of blood was needed. Human blood from the authors
SSF (female, 32) and IT (female, 37) was used for selected
extracts to verify an inhibitory eﬀect seen in sheep blood
at first screening. None of the human volunteers had been
exposed to antiplatelet medication for at least 2 weeks prior
to blood sampling. Venous blood was drawn with minimal
stasis using a 21G needle into Vacutainer tubes containing
3.2% (0.129M) sodium citrate (1 : 9), after discarding the
first 2mL.
Platelet-rich plasma (PRP) was prepared by centrifuga-
tion of citrated blood at 150×g for 10 minutes (human
blood) or 1200×g for 3 minutes (sheep blood) at 21◦C. Au-
tologous platelet-poor plasma (PPP) was prepared by cen-
trifugation of the remaining blood at 3000×g for 10min
at 21◦C. In each sample, the platelet count of the PRP
was determined by an automated counter (Medonic CA
620Vet, Boule Medical AB, London, UK), and based on
the count PRP was adjusted to the standard concentration
(250,000 platelets/μL). Platelet aggregation was performed by
standard procedures (Chronolog VS700, Chronolog Corp.,
Haverton, Pa, USA) with the following modifications: 225 μL
PRP and 25 μL agonist were used in all experiments. Platelet
poor plasma with DMSO : EtOH samples diluted 1 : 20 in
HEPES-tyrode’s buﬀer was used as reference to eliminate
bias of the extract colouring in the test. Final concentrations
of the agonists in sheep samples were 5 μg/mL collagen
(Chronolog Corp, Haverton, Pa, USA) and 5 μM adenosine
diphosphate (ADP—Bio/Data, Horsham, PA) and 2 μg/mL
collagen and 5 μM ADP in human samples. Extract and ve-
hicle control samples were analysed in parallel.
Aggregation response was recorded using the Aggrolink
software (Chronolog Corp). Maximal aggregation (MA) was
recorded in order to obtain a % inhibition of plant ex-
tract, comparing the vehicle control (HEPES-tyrode’s buﬀer
including BSA) with that of the plant extract %inhibition =
(MA vehicle control − MA extract)/MA vehicle control ∗
100%.
The experiments were approved by the Animal Experi-
ments Inspectorate under the Danish Ministry of Justice. All
human blood used was drawn from the authors themselves.
2.5. Initial Experiments in Aggregometer. Arachidonic acid
(AA), ADP and collagen were tested in several concentrations
in sheep blood in order to find the most suitable agonists and
the appropriate concentrations of these.
Based on the results from the initial experiment it was
decided to test AA in 500 μM, ADP in 5.0 μM, and collagen
in 2.5 μg/mL in an initial experiment, and from that, it was
decided to use ADP and collagen to all future experiments
in the aggregometer. The tested ADP concentration at
5.0 μM was suitable, whereas the collagen concentration was
increased from 2.5 μg/mL to 5.0 μg/mL. The aggregation
percentage in the collagen-induced reaction with vehicle
control was 61%, and by increasing the concentration of
agonist, the aggregation percentage would hopefully also
increase in order to get closer to the desired 70%. AA was
not used in any further experiments.
ADP and collagen were used as agonists based on the
initial experiments. For human blood, it was decided to lower
the collagen concentration to 2.0 μg/mL due to the observed
aggregation. The ADP concentration was the same (5.0 μM)
as in the experiment with sheep blood.
To establish the plant extract testing concentration, the
MeOH extract of the pharmacologically well described of
Drimys winteri [6] was tested in three diﬀerent concentra-
tions, 10, 1, and 0.1mg/mL. All three gave high inhibition
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Table 2: Mapuche medicinal plant extracts tested in sheep blood. The agonists are ADP (5.0 μM) and collagen (5.0 μg/mL) and the obtained
aggregations are shown in percentage. Extracts are tested in 0.1mg/mL end concentrations. The aggregation is shown for both extract and
vehicle control. If the extract aggregation is 20% lower than that of the vehicle control inhibition is observed.
Plant Extract
Extract Yield
(% dw)
Agonist
% Aggregation
(extract)
% Aggregation
(vehicle control)
% Inhibition Inhibition
Amomyrtus luma
(leaf)
DCM :MeOH
1 : 1
6.8
ADP 47 88 47 Yes
Collagen 25 85 71 Yes
MeOH 14.4
ADP 61 60 −2 No
Collagen 30 83 64 Yes
H2O 6.7
ADP 45 68 34 Yes
Collagen 23 86 73 Yes
Anthoxanthum
utriculatum (leaf)
DCM :MeOH
1 : 1
5.2
ADP 38 49 22 Yes
Collagen 106 124 15 ∗1
MeOH 4.9
ADP 33 68 51 Yes
Collagen 22 77 71 Yes
H2O 4.8
ADP 50 51 2 No
Collagen 39 75 48 Yes
Blechnum chilense
(leaf)
DCM :MeOH
1 : 1
2.8
ADP 52 62 16 No
Collagen 26 44 41 Yes
MeOH 1.8
ADP 38 52 27 Yes
Collagen 1 18 94 Yes
Cestrum parqui
(leaf)
DCM :MeOH
1 : 1
7.6
ADP 49 81 40 Yes
Collagen 27 91 70 Yes
MeOH 3.7
ADP 44 77 43 Yes
Collagen 30 83 64 Yes
H2O 15.9
ADP 73 82 11 ∗1
Collagen 52 82 37 Yes
Corynabutilon
vitifolium (leaf)
DCM :MeOH
1 : 1
3.6
ADP 48 54 11 No
Collagen 44 35 −26 No
MeOH 3.7
ADP 39 59 34 ∗1
Collagen 48 49 2 No
Fuchsia magellanica
(leaf)
DCM :MeOH
1 : 1
12.2
ADP 45 45 0 No
Collagen 10 12 17 No
MeOH 6.2
ADP 30 52 42 Yes
Collagen 32 38 16 No
Gunnera chilensis
(leaf + stem)
DCM :MeOH
1 : 1
13.1
ADP 50 59 15 No
Collagen 49 64 23 Yes
MeOH 3.3
ADP 40 56 29 ∗1
Collagen 35 65 46 Yes
H2O 6.5
ADP 50 71 30 ∗1
Collagen 68 56 −21 ∗1
Lomatia ferruginea
(leaf)
DCM :MeOH
1 : 1
2.7
ADP 24 55 56 Yes
Collagen 9 33 73 Yes
MeOH 1.1
ADP 43 50 14 No
Collagen 6 55 89 ∗2
H2O 6.9
ADP 57 43 −33 No
Collagen 30 50 40 ∗1
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Table 2: Continued.
Plant Extract
Extract Yield
(% dw)
Agonist
% Aggregation
(extract)
% Aggregation
(vehicle control)
% Inhibition Inhibition
Luma apiculata
(leaf)
DCM :MeOH
1 : 1
4.5
ADP 51 65 22 ∗1
Collagen 42 75 44 ∗1
MeOH 4.9
ADP 18 52 65 Yes
Collagen 20 64 69 Yes
H2O 9.1
ADP 19 56 66 Yes
Collagen 21 74 72 Yes
Pluchea absinthioides
(leaf)
DCM :MeOH
1 : 1
8.9
ADP 47 57 18 ∗1
Collagen 17 39 56 Yes
MeOH 2.9
ADP 48 50 4 No
Collagen 10 36 72 Yes
H2O 4.4
ADP 43 51 16 No
Collagen 9 51 82 ∗2
Pseudopanax
laetevirens (leaf)
DCM :MeOH
1 : 1
7.3
ADP 45 59 24 Yes
Collagen 23 61 62 Yes
MeOH 6.2
ADP 43 57 25 ∗1
Collagen 4 60 93 Yes
H2O 13.3
ADP 50 66 24 Yes
Collagen 8 6 −33 No
Satureja multiflora
(leaf + stem)
DCM :MeOH
1 : 1
7.2
ADP 44 74 41 Yes
Collagen 31 81 62 ∗1
MeOH 7.1
ADP 60 67 10 No
Collagen 44 125 65 ∗1
H2O 14.3
ADP 61 64 5 No
Collagen 11 43 74 ∗2
∗
1: Aggregation curve and output % does not correlate, and the result is doubtful.
∗2: Aggregation curve is very flat, this is suspicious.
with 0.1mg/mL yielding 38% (ADP agonist) and 90% (col-
lagen agonist) inhibition of sheep blood aggregation. Taking
into account that the 0.1mg/mL was also significantly easier
to dissolve in the testing buﬀers, it was decided to use this
concentration throughout the screening. This would still give
positive results for potent aggregation inhibitors.
2.6. Flow Cytometry. The DMSO : EtOH samples from Am-
omyrtis luma and Luma apiculata (1mg/mL) diluted in
HEPES-tyrode’s buﬀer containing BSA pH 7.4 was used
for flow cytometry experiments. 0.5% EtOH in HEPES-ty-
rode’s buﬀer with BSA was used as vehicle control. Citrated
human blood was incubated with DMSO : EtOH/HEPES-
tyrode’s samples (final concentration of 0.1mg/mL) or
vehicle control at 37◦C in 30 minutes.
Samples were assayed within 15 minutes from venipunc-
ture. Microcentrifuge tubes were prepared containing a mix-
ture of either HEPES-Tyrode’s buﬀer, phycoerythrin (PE)
conjugated anti-CD62P (Santa Cruz Biotechnology, Santa
Cruz, Calif, USA), fluorescein isothiocyanate (FITC) con-
jugated PAC-1 (Becton Dickinson, San Jose, Calif, USA),
or HEPES-Tyrode’s buﬀer, PE-Cy5-conjugated anti-CD42b
(Becton Dickinson), fluorescein isothiocyanate (FITC) con-
jugated PAC-1 (Becton Dickinson, San Jose, Calif, USA)
and eptifibatide. To both mixes platelet agonist was added
for the detection of platelet surface P-selectin and activated
GPIIb/IIIa. Pilot experiments using several diﬀerent agonist
concentrations were performed to identify agonist concen-
trations giving maximal and submaximal platelet activation.
Final concentrations of agonists in the reaction mixture
were 1 or 5 μM of thrombin receptor activating peptide
(TRAP, Sigma-Aldrich, Brondby, Denmark), 0.5 or 20 μM
of ADP (Bio/Data Co., Horsham, Pa, USA), or no agonist
(HEPES-Tyrode’s buﬀer). All ADP and TRAP dilutions were
made as batches and stored at −20◦C along with vehicle
control for the controls to minimize dilution variation. An-
tibody mixtures were prepared as batches and kept at 4◦C.
After incubation, P-selectin and activated GPIIbIIIa samples
were fixed by 1% formaldehyde in HEPES-saline. Samples
were analyzed in an FACSCalibur (Becton Dickinson) flow
cytometer. Platelets were identified by light scatter properties
and expression of CD42b. All samples were tested in trip-
licates.
3. Results
3.1. Platelet Aggregation in Sheep Blood. After conducting
the initial experiments, a total of 33 extracts, from 12
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diﬀerent plants were screened in ADP (5.0 μM) and colla-
gen (5.0 μg/mL) induced aggregations in the aggregometer.
Table 2 shows the average reading of duplicates and whether
or not the plant extracts were able to inhibit ADP and col-
lagen induced aggregation. All extract was compared towards
the vehicle control and if the observed aggregation was 20%
lower for extract test than for the vehicle is was concluded
that the extract inhibited aggregation. Additionally, all ex-
tracts was tested with two diﬀerent inducers, this further sup-
port the validity of the inhibition results.
Plant samples that in a convincing way were able to
inhibit the aggregation in sheep blood were subsequently
tested in a similar experiment with human blood. The below
seven plants in the respective extracts were the ones chosen
to be tested again.
The DCM :MeOH 1 : 1 extracts of Amomyrtus luma,
Blechnum chilense, Cestrum parqui, Lomatia ferruginea, and
Pseudopanax laetevirens were active as were the MeOH
extracts of A. luma, Anthoxanthum utriculatum B. chilense,
C. parqui, Luma apiculata, and P. laetevirens, and the water
extracts ofA. luma,C. parqui, and L. apiculata. These samples
were all chosen to be tested in human blood.
3.2. Platelet Aggregation in Human Blood. Seven of the
species tested in sheep blood was tested in human blood.
The activity is listed in Table 3. The four plants A. luma
(DCM :MeOH 1 : 1 extract), B. chilense (MeOH extract),
C. parqui (DCM :MeOH 1 : 1 extract), and L. apiculata (H2O
extract) showed inhibitory eﬀect in both sheep and human
blood in both ADP- and collagen induced aggregations (see
Tables 2 and 3). Furthermore, the H2O extract from A. luma
showed inhibition in the collagen induced aggregation.
3.3. Flow Cytometry. In order to confirm the obtained results
from the aggregation experiments the A. lumaDCM :MeOH
1 : 1 extract and the L. apiculata H2O extract were tested
for inhibition of platelet surface activation markers flow cy-
tometry.
Table 4 shows the tested extracts and the percent in-
hibition of PAC1 MFI and CD62P (P-selectin) MFI by ad-
dition of ADP (0.5 μM and 20 μM) and the human specific
inducer TRAP (1.0 μM and 5.0 μM). PAC1 and CD62P are
both markers of platelet activation, and in order to be
assigned an inhibitory eﬀect the extracts should inhibit both
activation markers using both agonists at all concentrations.
The extracts from L. apiculata andA. luma showed clearly
inhibitory eﬀect of both PAC1 MFI and CD62P MFI in
the tested ADP concentrations as well as with the addition
of 1.0 μM TRAP, whereas only a slight inhibitory eﬀect is
observed when 5.0 μM TRAP was added. TRAP was used in
the flow cytometry assays since it is a human specific platelet
inducer.
4. Discussion
The four plants Amomyrtus luma, Blechnum chilense, Ces-
trum parqui, and Luma apiculata showed inhibitory eﬀect
in both sheep and human blood in both ADP and collagen
induced aggregations. Of these L. apiculata (H2O extract)
and A. luma (DCM :MeOH 1 : 1 extract) was the most prom-
inent candidates for further examinations. The two extracts
were examined using platelet specific markers PAC1 and
CD62P and the human-specific inducer TRAP and ADP in
a flow cytometry assay. PAC1 and CD62P (P-selectin) does
not bind to resting platelets but only to activated platelets
[19]. These studies showed clear platelet inhibitory eﬀect on
platelet surface activation markers by the two markers as
shown in Table 4. The eﬀect observed in the flow cytometry
confirms the results seen in the aggregometer.
The ethanol extract of the leaves of A. luma has been
shown to contain 1-phenylpentan-3-one (4.6/8.5%) and 1-
phenylhexan-3-one (3.5/12.3%) as well as β-caryophyllene
oxide (10.7/6.6%) and linalool (59.3/11.3%) [20], of these
the β-caryophyllene oxide has been shown to spontaneously
aggregate blood platelets [21] at 100 μg/mL concentrations.
This eﬀect contradicts the observed eﬀect of the extract,
where aggregations was inhibited and suggest a strong inhibi-
tion of the organic extracts of A. luma since β-caryophyllene
oxide would have been extracted with both DCM :MeOH
1 : 1 and to some extend also MeOH. The presence of β-
caryophyllene oxide could be part of the explanation on why
no inhibition was observed for the MeOH extract using ADP
as an inducer. Further studies are needed to determine the
active constituents in A. luma.
The MeoH extracts of B. chilensis have previously been
shown to have antimicrobial eﬀects [3]. L. apiculata have
previously been shown to have xanthine oxidase inhibitory
activity (30% inhibition at 50 μg/mL EtOH :H2O 7 : 3
extract) [22], and antiviral activity on herpes (IC50 =
100 μg/mL, EtOH extract) [23]. But none of these studies
provides information to what could be active constituent,
and no phytochemical data was found for these two species.
COX inhibitory activity indirectly inhibiting P-selectin
expression on human platelets [24]. It has been demon-
strated that caﬀedymine from cocoa, have COX inhibitory
activity, with 43% inhibition of COX-1 at 0.01 μM, and
that caﬀedymine suppress P-selectin (CD62P) expression on
platelets by 33% at a concentration of 0.05 μM [24]. The
inhibition of COX enzymes may be a main contributing
factor to suppressing P-selectin expression [24], which could
be the eﬀect observed with extracts of L. apiculata and A.
luma. In order to confirm or invalidate this theory, COX
inhibitory eﬀect of L. apiculata and A. luma would have to
be examined. Several plant extracts have already been tested
for their COX activity [25] and this would need to evaluated
along with determination of the active constituents.
It has previously been shown, that a MeOH :H2O 1 : 1
extract from C. parqui was able to inhibit aggregation of
human blood platelets induced by ADP [26]. This confirms
that some extracts from C. parqui are able to inhibit ADP
induced platelet aggregations. However, the same was not
observed in an AA-induced platelet aggregation, which
implies that, the extracts anti-inflammatory activity did not
implicate the inhibition of the cyclooxygenase pathway, that
has been seen in other studies [27]. A suggestion is that the
extract inhibited a site upstream of AAmetabolism, since the
case might be that ADP has triggered the release of AA in the
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Table 3: Seven plant species that showed inhibitory eﬀect in sheep blood were subsequently tested in human blood. The agonists are ADP
(5.0 μM) and collagen (2.0 μg/mL) and the obtained aggregations are shown in percent. Extracts are tested in 0.1mg/mL end concentrations.
The aggregation is shown for both extract and vehicle control. If the extract aggregation is 20% lower than that of the vehicle control
inhibition is observed.
Plant Extract Agonist
% Aggregation
(extract)
% Aggregation (vehicle
control)
% Inhibition Inhibition
Amomyrtus luma
(leaf)
DCM :MeOH
1 : 1
ADP 57 73 22 Yes
Collagen 62 87 29 Yes
MeOH
ADP 66 70 6 No
Collagen 68 70 3 No
H2O
ADP 66 69 4 No
Collagen 60 76 21 Yes
Anthoxanthum
utriculatum (leaf)
MeOH
ADP 63 64 2 No
Collagen 63 68 7 No
Blechnum chilense
(leaf)
DCM :MeOH
1 : 1
ADP 73 77 5 No
Collagen 74 73 −1 No
MeOH
ADP 60 83 28 Yes
Collagen 61 86 29 Yes
Cestrum parqui (leaf)
DCM :MeOH
1 : 1
ADP 61 84 27 Yes
Collagen 67 84 20 Yes
MeOH
ADP 70 70 0 No
Collagen 71 71 0 No
H2O
ADP 74 71 −4 No
Collagen 64 68 6 No
Lomatia ferruginea
(leaf)
DCM :MeOH
1 : 1
ADP 72 72 0 No
Collagen 73 71 −3 No
Luma apiculata (leaf)
MeOH
ADP 70 67 −4 No
Collagen 65 71 8 No
H2O
ADP 46 84 45 Yes
Collagen 54 85 36 Yes
Pseudopanax
laetevirens (leaf)
DCM :MeOH
1 : 1
ADP 69 72 4 No
Collagen 66 72 8 No
MeOH
ADP 69 72 4 No
Collagen 69 76 9 No
Table 4: Flow cytometry results from L. apiculata H2O extract, and A. luma DCM :MeOH 1 : 1 extract. Inhibitions of the platelet activation
markers, PAC1 and CD62P are shown in percent compared with vehicle control. The agonist is ADP in 0.5 μM and 20.0 μM, and TRAP in
1.0 μM and 5.0 μM. Extracts are tested in 0.1mg/mL end concentrations.
Plant extract
% Inhibition of PAC1 MFI % inhibition of CD62P MFI
ADP
0.5 μM
ADP
20.0 μM
TRAP
1.0 μM
TRAP
5.0 μM
ADP
0.5 μM
ADP
20.0 μM
TRAP
1.0 μM
TRAP
5.0 μM
Luma apiculata (H2O
extract)
34.4 20.1 74.1 8.0 38.9 28.1 80.7 3.5
Amomyrtus luma
(DCM :MeOH 1 : 1 extract)
30.1 17.8 78.1 12.4 37.7 27.4 83.2 6.4
pathway [26]. These data could explain the data observed and
the two datasets suggest that C. parqui contains several active
constituents. The plant itself have long been known to cause
poisoning in cows, and it has been shown that the toxicity
is in the organic phase that contained low molecular weight
phenols [28], among these flavonoids that as mentioned have
been shown to have antiplatelet activity. With more than 150
publication on C. parqui and its pharmacology and several
toxic and pharmacologically active terpenoids isolated from
the plant [29] further studies are not of high priority.
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5. Conclusion
In the present work, four Chilean plant species were shown
to inhibit platelet aggregating induced by ADP and collagen
in both sheep and human blood. The four species were Blech-
num chilense (MeOH extract), Luma apiculata (H2O ex-
tract), Amomyrtus luma (DCM :MeOH 1 : 1 extract) and
Cestrum parqui (DCM :MeOH 1 : 1 extract). The platelet
aggregating inhibitory eﬀects of A. luma (DCM :MeOH 1 : 1
extract) and L. apiculata (H2O extract) were furthermore
confirmed by inhibition of platelet surface activation mark-
ers.
At present, there is still a great need for preventative
and therapeutic, anticoagulant medicine, and plants and
their fruits seem to constitute possible alternatives to drugs
currently used. It is of great interest to explore this inhibition
further for the three species B. chilense, L. apiculata, A. luma.
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